We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    CM-101
Previous Study | Return to List | Next Study

CM-101 in PSC Patients -The SPRING Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT04595825
Recruitment Status : Recruiting
First Posted : October 22, 2020
Last Update Posted : September 2, 2021
Information provided by (Responsible Party):
ChemomAb Ltd.

Brief Summary:
This study is designed to assess the safety, tolerability and activity of CM-101 in patients with Primary Sclerosing Cholangitis (PSC).

Condition or disease Intervention/treatment Phase
Primary Sclerosing Cholangitis Biological: CM-101 Other: Placebo Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 45 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Clinical Trial Evaluating The Safety And Efficacy Of CM-101 In Subjects With Primary Sclerosing Cholangitis- The SPRING Study
Actual Study Start Date : October 1, 2020
Estimated Primary Completion Date : June 2022
Estimated Study Completion Date : September 2022

Arm Intervention/treatment
Experimental: CM-101 Biological: CM-101
CM-101, Monoclonal Ab blocking CCL24

Placebo Comparator: Placebo Other: Placebo

Primary Outcome Measures :
  1. Alkaline Phosphatase Levels (ALP) [ Time Frame: 15 weeks ]
    Mean and percent change in ALP from baseline to Week 15

  2. Enhanced Liver Fibrosis (ELF) [ Time Frame: 15 weeks ]
    Mean change from baseline to Week 15 in Enhanced Liver Fibrosis (ELF) score

Secondary Outcome Measures :
  1. Change in liver enzymes [ Time Frame: 15 weeks ]
    Percent change from baseline over time in liver enzymes (ALT, AST and GGT)

  2. Liver fibrosis markers [ Time Frame: 15 weeks ]
    Change from baseline to Week 15 in liver fibrosis markers such as PRO-C3 and PRO-C5

  3. PK profile [ Time Frame: 15 weeks ]
    Measurement of the serum CM-101 levels following repeated CM-101 administrations

  4. Anti-drug antibodies [ Time Frame: up to 27 weeks ]
    Evaluation of the development of anti-drug antibodies (ADA) following repeated CM-101 administrations

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Diagnosis of large duct PSC of > 24 weeks' duration
  • No significant clinical concern for cholangiocarcinoma based on clinical, laboratory or imaging findings
  • Subjects with concomitant IBD must have recent colonoscopy with biopsy confirming no dysplasia or cancer.
  • Subjects with IBD must be in remission and have stable disease
  • ConMed stable ≥12 weeks prior to randomization (including stable dose)
  • Female subjects of childbearing potential, effective method of contraception from the Screening visit to 18 weeks post last dose
  • Able to understand and sign ICF

Exclusion Criteria:

  • Clinically significant causes or manifestations of sclerosing cholangitis other than PSC
  • Patient that are planned for or post liver transplantation
  • Patients with evidence of liver cirrhosis
  • History of cholangiocarcinoma or a high clinical suspicion for cholangiocarcinoma
  • Pregnant or breast feeding women

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04595825

Show Show 21 study locations
Sponsors and Collaborators
ChemomAb Ltd.
Layout table for additonal information
Responsible Party: ChemomAb Ltd.
ClinicalTrials.gov Identifier: NCT04595825    
Other Study ID Numbers: CM-101-PSC-101
First Posted: October 22, 2020    Key Record Dates
Last Update Posted: September 2, 2021
Last Verified: September 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by ChemomAb Ltd.:
Additional relevant MeSH terms:
Layout table for MeSH terms
Cholangitis, Sclerosing
Bile Duct Diseases
Biliary Tract Diseases
Digestive System Diseases